Satyanarayana Chintala

Dr. Satyanarayana Chintala

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 February 2023 in Biomolecules
Verified
Journal Article
Open access
PDF file
HTHiroki Tateiwa
Hiroki Tateiwa
SCSatyanarayana Chintala
Satyanarayana Chintala
ZCZiwei Chen
Ziwei Chen
LWLei Wang
Lei Wang
FAFatima Amtashar
Fatima Amtashar
AEAlex S Evers
Alex S Evers
The neurosteroid allopregnanolone (ALLO) and pregnanolone (PREG), are equally effective positive allosteric modulators (PAMs) of GABAA receptors. Interestingly, the PAM effects of ALLO are strongly enantioselective, whereas those of PREG are not. This study was aimed at determining the basis for this difference in enantioselectivity. The oocyte electrophysiology studies showed that ent-ALLO potentiates GABA-elicited currents in α1β3 GABAA receptors with lower potency and efficacy than ALLO, PREG or ent-PREG. The small PAM effect of ent-ALLO was prevented by the α1(Q242L) mutation in the intersubunit neurosteroid binding site between the β3 and α1 subunits. Consistent with this result, neurosteroid analogue photolabeling with mass spectrometric readout, showed that ent-ALLO binds weakly to the β3-α1 intersubunit binding site in comparison to ALLO, PREG and ent-PREG. Rigid body docking predicted that ent-ALLO binds in the intersubunit site with a preferred orientation 180° different than ALLO, PREG or ent-PREG, potentially explaining its weak binding and effect. Photolabeling studies did not identify differences between ALLO and ent-ALLO binding to the α1 or β3 intrasubunit binding sites that also mediate neurosteroid modulation of GABAA receptors. The results demonstrate that differential binding of ent-ALLO and ent-PREG to the β3-α1 intersubunit site accounts for the difference in enantioselectivity between ALLO and PREG.

15 July 2020 in RSC Advances
Verified
Journal Article
Open access
PDF file
JPJohn T. Petroff
John T. Petroff
AIAnkita Isor
Ankita Isor
SCSatyanarayana Chintala
Satyanarayana Chintala
CACarolyn J. Albert
Carolyn J. Albert
JFJacob D. Franke
Jacob D. Franke
RMRyan D. McCulla
Ryan D. McCulla
Lipophilic O(3P)-precursors generate 2-hexadecenal upon UV-irradiation.

22 April 2021 in bioRxiv
Verified
Preprint
Open access
PDF file
SCSoumen Chakraborty
Soumen Chakraborty
JDJeffrey F. DiBerto
Jeffrey F. DiBerto
AFAbdelfattah Faouzi
Abdelfattah Faouzi
SBSarah M. Bernhard
Sarah M. Bernhard
AGAnna M. Gutridge
Anna M. Gutridge
SMSusruta Majumdar
Susruta Majumdar
Dried kratom leaves are anecdotally used for the treatment of pain, opioid dependence, and alcohol use disorder. We have previously shown that kratom’s natural products (mitragynine) and semi-synthetic analogs (7-hydroxy mitragynine (7OH) and mitragynine pseudoindoxyl) are mu opioid receptor (MOR) agonists that show minimal β-arrestin2 recruitment. To further investigate the structure activity relationships of G-protein potency, efficacy, and β-arrestin2 recruitment, we diversified the mitragynine/7OH templates at the C9, -10 and -12 positions of the aromatic ring of the indole moiety. Three lead C9 analogs, synthesized by swapping the 9-methoxy group with varied substituents, namely phenyl ( SC11 ), methyl ( SC12 ), 3’-furanyl ( SC13 ), were further characterized using a panel of in vitro and ex vivo electrophysiology assays. All three compounds were partial agonists with lower efficacy than both DAMGO and morphine in heterologous G-protein assays and synaptic physiology. SC11-13 also showed lower recruitment of both β-arrestin subtypes compared to DAMGO, and in assays with limited MOR receptor reserve, the G-protein efficacy of SC11, SC12 and SC13 was comparable to buprenorphine. In mouse models, at equianalgesic doses SC13 showed MOR-dependent analgesia with potency similar to morphine without respiratory depression, hyperlocomotion, constipation, or place conditioning. Taken together, these results suggest that MOR agonists with a G-protein efficacy profile similar to buprenorphine can be developed into opioids that are effective analgesics with greatly reduced liabilities.